These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8758094)

  • 1. Successful treatment of visceral leishmaniasis with high-dose amphotericin B diluted in fat emulsion: a case report.
    Herbrecht R; Sosa C; Himy R; Villard O
    Trans R Soc Trop Med Hyg; 1996; 90(3):322-3. PubMed ID: 8758094
    [No Abstract]   [Full Text] [Related]  

  • 2. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

  • 4. [Subacute Mediterranean visceral leishmaniosis treated with a single injection of amphotericin B].
    Vandenbos F; Marty P; Rosenthal E; Delaunay P; Dellamonica P; Le Fichoux Y
    Presse Med; 2004 Sep; 33(15):1009-10. PubMed ID: 15523248
    [No Abstract]   [Full Text] [Related]  

  • 5. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Berman JD
    Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
    [No Abstract]   [Full Text] [Related]  

  • 6. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis.
    Sundar S; Gupta LB; Rastogi V; Agrawal G; Murray HW
    Trans R Soc Trop Med Hyg; 2000; 94(2):200-4. PubMed ID: 10897369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 8. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients.
    Gaeta GB; Maisto A; Di Caprio D; Scalone A; Pasquale G; Felaco FM; Galante D; Gradoni L
    Scand J Infect Dis; 2000; 32(6):675-7. PubMed ID: 11200380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
    Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
    Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B.
    Bodhe PV; Pathare AV; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 1996 Mar; 44(3):222. PubMed ID: 9251329
    [No Abstract]   [Full Text] [Related]  

  • 13. Visceral leishmaniasis during pregnancy: A rare case report from Greece.
    Panagopoulos P; Mitsopoulos V; Papadopoulos A; Theodorou S; Christodoulaki C; Aloupogiannis K; Papantoniou N
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005134. PubMed ID: 28207741
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 15. Visceral leishmaniasis complicating idiopathic CD4+ T-cell lymphocytopenia: 2 case reports.
    Fox-Lewis A; Lockwood DNJ
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005412. PubMed ID: 28493863
    [No Abstract]   [Full Text] [Related]  

  • 16. Visceral leishmaniasis: rapid response to AmBisome treatment.
    Smith OP; Hann IM; Cox H; Novelli V
    Arch Dis Child; 1995 Aug; 73(2):157-9. PubMed ID: 7574862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose liposomal amphotericin B for visceral leishmaniasis.
    Kshirsagar NA
    Lancet Glob Health; 2014 Apr; 2(4):e203. PubMed ID: 25103058
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol.
    Khodabandeh M; Rostami A; Borhani K; Gamble HR; Mohammadi M
    Parasitol Int; 2019 Oct; 72():101934. PubMed ID: 31129197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B.
    Mishra M
    J Assoc Physicians India; 1995 Apr; 43(4):306. PubMed ID: 8713286
    [No Abstract]   [Full Text] [Related]  

  • 20. Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis.
    Castagnola E; Davidson RN; Fiore P; Tasso L; Rossi G; Mangraviti S; Di Martino L; Scotti S; Cascio A; Pempinello R; Gradoni L; Giacchino R
    Trans R Soc Trop Med Hyg; 1996; 90(3):317-8. PubMed ID: 8758092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.